Position in DNLI
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$14,553
+$2,039 QoQ
Shares Held
758
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2021
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026QUADRANT CAPITAL GROUP LLC holds $22,827,015 across 21 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
2,887 | $2,678,471 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,938 | $2,452,852 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,691 | $2,301,486 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
5,658 | $1,788,437 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
49,246 | $1,742,815 | |
| 6 | EXEL |
Exelixis, Inc.
|
30,229 | $1,644,759 | |
| 7 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
2,605 | $1,398,754 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
4,647 | $1,324,255 |
All Filings in DNLI
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14,553 | 758 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $12,514 | 758 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $11,354 | 782 | Shares | Sole | 2025-11-13 | |
| 2025-03-31 | $7,001 | 515 | Shares | Sole | 2025-05-13 | |
| 2023-12-31 | $407 | 19 | Shares | Sole | 2024-02-08 | |
| 2023-09-30 | $144 | 7 | Shares | Sole | 2023-11-14 | |
| 2022-12-31 | $1,112 | 40 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $1,534 | 50 | Shares | Sole | 2022-11-10 | |
| 2021-09-30 | $151 | 3 | Shares | Sole | 2021-11-12 | |
| No filing history on record for this holder in this stock. | ||||||